Cargando…
Bilobar Radioembolization Carries the Risk of Radioembolization-Induced Liver Disease in the Treatment of Advanced Hepatocellular Carcinoma: Safety and Efficacy Comparison to Systemic Therapy with Atezolizumab/Bevacizumab
SIMPLE SUMMARY: Treatment options for intermediate- or advanced-stage hepatocellular carcinoma include trans-arterial radioembolization of the whole liver and systemic therapy. While no significant difference in overall survival has been reported for patients receiving radioembolization or sorafenib...
Autores principales: | Jeschke, Matthias, Ludwig, Johannes M., Leyh, Catherine, Pabst, Kim M., Weber, Manuel, Theysohn, Jens M., Lange, Christian M., Herrmann, Ken, Schmidt, Hartmut H. -J., Jochheim, Leonie S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486761/ https://www.ncbi.nlm.nih.gov/pubmed/37686549 http://dx.doi.org/10.3390/cancers15174274 |
Ejemplares similares
-
Prognostic Factors for Overall Survival in Advanced Intrahepatic Cholangiocarcinoma Treated with Yttrium-90 Radioembolization
por: Köhler, Michael, et al.
Publicado: (2019) -
LiMAx Prior to Radioembolization for Hepatocellular Carcinoma as an Additional Tool for Patient Selection in Patients with Liver Cirrhosis
por: Leyh, Catherine, et al.
Publicado: (2022) -
The physics of radioembolization
por: Bastiaannet, Remco, et al.
Publicado: (2018) -
A single-center experience in radioembolization as salvage therapy of hepatic metastases of uveal melanoma
por: Schelhorn, Juliane, et al.
Publicado: (2015) -
Prediction of left lobe hypertrophy after right lobe radioembolization of the liver using a clinical data model with external validation
por: Theysohn, Jens M., et al.
Publicado: (2022)